Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Oncology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients
- Oncology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers
- Oncology
- AMA PRA Category 1 Credit™
- Participation
$0.00
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo.
- Oncology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Antibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs. David Ilson and Kohei Shitara as they discuss emerging data from select clinical trials evaluating combinations of HER2-targeted therapies for patients with gastric cancer.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo.
- Oncology
- AMA PRA Category 1 Credit™
- Participation
$0.00
Clinicians must be aware and up-to-date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Join Drs. David Ilson and Yelena Janjigian as they discuss the rapidly evolving landscape of gastric cancer treatment, focusing on available front- and subsequent-lines of treatment, and how to tailor treatment to patients based on health status, prior lines of therapy, cost, convenience and access to care, genetic aberrations, and availability of a clinical trial.
- Oncology
- AAPA Category I CME
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer.
- Oncology
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them. If irAEs do develop, it is essential to arrive at an early diagnosis and use aggressive systemic corticosteroids when necessary to prevent life-threatening consequences.
- Oncology
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
- Oncology
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs.